In a report issued on November 9, Maury Raycroft from Jefferies reiterated a Buy rating on Alnylam Pharma (ALNY), with a price target of $122. The company’s shares opened today at $68.32, close to its 52-week low of $63.61.
According to TipRanks.com, Raycroft is a 4-star analyst with an average return of 6.7% and a 32.3% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, KalVista Pharmaceuticals Inc, and Logicbio Therapeutics Inc.
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $142.25, a 108.2% upside from current levels. In a report issued on November 7, Cowen & Co. also maintained a Buy rating on the stock with a $147 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $153.99 and a one-year low of $63.61. Currently, Alnylam Pharma has an average volume of 975.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
